GlaxoSmithKline may be suffering from R&D setbacks, generic competition and corruption investigations in a dozen countries, but its HIV-oriented venture ViiV Healthcare is racking up new OKs. Friday, the company scored the FDA's blessing for a combo drug pegged at $5 billion in peak sales.
A new strategy that uses broadly neutralizing antibodies combined with a cocktail of viral-inducing compounds may be able to stop HIV from rebounding, according to researchers at Rockefeller University.
Researchers at the University of Washington have developed a medicated, electrospun fabric that could prevent HIV infections in women.
Without explaining why, AbbVie has decided not to appeal a court ruling that extended rights to gay jurors which materialized out of litigation it has been waging with GlaxoSmithKline over the pricing of an HIV med. But it is seldom a good idea for a pharma company to antagonize its patient base. And gay men make up a significant number of the patients on HIV drugs sold by the drugmaker.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.
A new discovery of an ancestral fossil virus buried within everyone's genomes might provide the key to eradicating HIV.
Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.
Norway's Bionor Pharma and U.K. scientists claim they've identified a biomarker in some patients that may be connected with an improved response to a therapeutic HIV vaccine now under development.
A novel intravaginal ring to prevent HIV showed promise in pig-tailed macaque monkeys, demonstrating the benefits of sustained and controlled topical drug delivery over oral intake.
Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' dominance in the field.